CYTT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CYTT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Cyteir Therapeutics's total current assets for the quarter that ended in Sep. 2023 was $130.64 Mil.
The historical data trend for Cyteir Therapeutics's Total Current Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cyteir Therapeutics Annual Data | |||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | |||||
Total Current Assets | 30.44 | 12.13 | 193.08 | 149.21 |
Cyteir Therapeutics Quarterly Data | ||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | |
Total Current Assets | Get a 7-Day Free Trial | 157.35 | 149.21 | 138.39 | 133.91 | 130.64 |
Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.
Cyteir Therapeutics's Total Current Assets for the fiscal year that ended in Dec. 2022 is calculated as
Total Current Assets | = | Cash, Cash Equivalents, Marketable Securities | + | Total Receivables | + | Total Inventories | + | Other Current Assets |
= | 147.12 | + | 0 | + | 0 | + | 2.089 | |
= | 149.21 |
Cyteir Therapeutics's Total Current Assets for the quarter that ended in Sep. 2023 is calculated as
Total Current Assets | = | Cash, Cash Equivalents, Marketable Securities | + | Total Receivables | + | Total Inventories | + | Other Current Assets |
= | 129.242 | + | 0.017 | + | 0 | + | 1.384 | |
= | 130.64 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.
Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.
Cyteir Therapeutics (OTCPK:CYTT) Total Current Assets Explanation
In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.
Cyteir Therapeutics's Liquidation Value for the quarter that ended in Sep. 2023 is
Liquidation value | |||||||
= | Cash, Cash Equivalents, Marketable Securities | - | Total Liabilities | + | (0.75 * Accounts Receivable) | + | (0.5 * Total Inventories) |
= | 129.242 | - | 5.978 | + | 0.75 * 0 | + | 0.5 * 0 |
= | 123.26 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Cyteir Therapeutics's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Novo Holdings A/s | 10 percent owner | TUBORG HAVNEVEJ 19, HELLERUP G7 2900 |
Joseph S Zakrzewski | director | 509 WATERVIEW PLACE, NEW HOPE PA 18938 |
John F Thero | director | C/O AMARIN PHARMA, INC., 1430 ROUTE 6, BEDMINSTER NJ 07921 |
Adam M Veness | officer: General Counsel | C/O DIANTHUS THERAPEUTICS, INC., 7 TIMES SQUARE, 43RD FLOOR, NEW YORK NY 10036 |
Stephen H. Sands | director | 128 SPRING STREET, BUILDING A, SUITE 510, LEXINGTON MA 02421 |
Jeffrey Humphrey | director | C/O CONSTELLATION PHARMACEUTICALS, INC., 215 FIRST STREET, SUITE 200, CAMBRIDGE MA 02142 |
Droia Invest Ii Scsp | 10 percent owner | 28 BOULEVARD JOSEPH II, LUXEMBOURG N4 L-1840 |
Janwillem Naesens | director | 128 SPRING STREET, BUILDING A, SUITE 510, LEXINGTON MA 02421 |
Sa Ihl | 10 percent owner | 28 BOULEVARD JOSEPH II, LUXEMBOURG N4 L-1840 |
Karen Hong | director | 69 PARKSIDE DRIVE, PRINCETON NJ 08540 |
Bv Wepaven | 10 percent owner | BRUSSELSESTEENWEG 11, MEISE C9 1860 |
Luc Verelst | 10 percent owner | 28 BOULEVARD JOSEPH II, LUXEMBOURG N4 L-1840 |
Df Ii Gp Sarl | 10 percent owner | 28 BOULEVARD JOSEPH II, LUXEMBOURG N4 L-1840 |
Timothy Romberger | director | 128 SPRING STREET, BUILDING A, SUITE 510, LEXINGTON MA 02421 |
Racquel Bracken | director | 128 SPRING STREET, BUILDING A, SUITE 510, LEXINGTON MA 02421 |
From GuruFocus
By Business Wire Business Wire • 01-19-2023
By Business Wire Business Wire • 02-07-2022
By Business Wire Business Wire • 05-31-2022
By Business Wire Business Wire • 09-01-2021
By Business Wire Business Wire • 08-08-2022
By Business Wire Business Wire • 02-08-2022
By Business Wire • 03-07-2024
By Business Wire Business Wire • 06-05-2022
By Business Wire • 06-30-2023
By Business Wire Business Wire • 02-06-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.